Published in Ann Pharmacother on June 04, 2013
Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model. PLoS Negl Trop Dis (2016) 1.41
Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review. J Clin Pharm Ther (2016) 0.75
Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol (2017) 0.75
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother (2008) 3.12
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother (2008) 2.70
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther (2010) 2.60
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother (2006) 2.31
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother (2012) 2.05
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother (2006) 1.75
Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis (2010) 1.60
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.39
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother (2007) 1.29
Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis (2008) 1.27
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24
Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy (2011) 1.07
Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob Agents Chemother (2011) 1.05
Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm (2009) 1.05
A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents (2011) 1.03
Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit (2011) 0.90
Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit (2012) 0.88
Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Des Devel Ther (2010) 0.82
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy (2009) 2.31
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother (2007) 1.94
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc (2013) 1.80
Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med (2009) 1.79
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol (2007) 1.67
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66
ACCP: economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy (2009) 1.66
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother (2005) 1.57
Recruitment and retention of adolescent participants in HIV research: findings from the REACH (Reaching for Excellence in Adolescent Care and Health) Project. J Adolesc Health (2003) 1.52
Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics (2008) 1.49
Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis (2011) 1.49
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet (2014) 1.49
Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer (2007) 1.47
Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology (2005) 1.47
Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. Pediatrics (2006) 1.45
Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis (2010) 1.44
National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm (2013) 1.43
Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma. Pediatr Blood Cancer (2013) 1.41
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect (2006) 1.38
Newer treatments for fungal infections. J Support Oncol (2005) 1.38
Biosimilars: Implications for health-system pharmacists. Am J Health Syst Pharm (2013) 1.36
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J (2005) 1.34
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26
Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS (2008) 1.22
Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer (2008) 1.22
Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol (2009) 1.20
Projecting future drug expenditures: 2011. Am J Health Syst Pharm (2011) 1.16
The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol (2003) 1.13
Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses (2006) 1.11
Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis (2004) 1.11
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis (2012) 1.09
Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retroviruses (2010) 1.08
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf (2010) 1.08
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics (2009) 1.05
Infections in children and young adults with bone malignancies undergoing limb-sparing surgery. Cancer (2005) 1.04
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol (2009) 1.03
Implementation of and barriers to routine HIV screening for adolescents. Pediatrics (2009) 1.01
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther (2011) 1.00
Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer (2012) 0.99
Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy (2014) 0.98
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother (2013) 0.97
Improved sensitivity for methotrexate analysis using enzyme multiplied immunoassay technique on the Siemens Viva-E instrument. Ther Drug Monit (2012) 0.96
Early patterns of adherence in adolescents initiating highly active antiretroviral therapy predict long-term adherence, virologic, and immunologic control. AIDS Patient Care STDS (2009) 0.96
Two cases with unusual vancomycin measurements. Clin Chem (2009) 0.96
Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. J Adolesc Health (2010) 0.95
Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy. Med Care (2005) 0.95
National trends in prescription drug expenditures and projections for 2014. Am J Health Syst Pharm (2014) 0.95
Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J (2010) 0.95
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol (2006) 0.94
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol (2009) 0.94
Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (2004) 0.93
SHP-1 inhibits LPS-mediated TNF and iNOS production in murine macrophages. Biochem Biophys Res Commun (2006) 0.93
Diagnosis of catheter-related bloodstream infections among pediatric oncology patients lacking a peripheral culture, using differential time to detection. Pediatr Infect Dis J (2005) 0.93
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics (2011) 0.93
Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer (2014) 0.93
NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders. J Natl Compr Canc Netw (2010) 0.92
Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother (2006) 0.92
A cultural research approach to instrument development: the case of breast and cervical cancer screening among Latino and Anglo women. Health Educ Res (2010) 0.92
High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.91
High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med (2013) 0.90
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol (2005) 0.90
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics (2014) 0.89
Optimizing blood culture practices in pediatric immunocompromised patients: evaluation of media types and blood culture volume. Pediatr Infect Dis J (2003) 0.88
Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother (2007) 0.87
Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. Pediatr Infect Dis J (2010) 0.87
Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth. Hum Genet (2009) 0.87
Delayed entry into and failure to remain in HIV care among HIV-infected adolescents. AIDS Res Hum Retroviruses (2012) 0.87
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood (2013) 0.87
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer (2010) 0.87
Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis. J Pediatr (2010) 0.86
Short communication: methicillin-resistant Staphylococcus aureus infections in children and young adults infected with HIV. AIDS Res Hum Retroviruses (2009) 0.86
In situ diagnosis of central venous catheter-related bloodstream infection without peripheral blood culture. Pediatr Infect Dis J (2004) 0.86
Difference in time to detection: a simple method to differentiate catheter-related from non-catheter-related bloodstream infection in immunocompromised pediatric patients. Clin Infect Dis (2003) 0.86
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer (2011) 0.85
Development of a directly observed therapy adherence intervention for adolescents with human immunodeficiency virus-1: application of focus group methodology to inform design, feasibility, and acceptability. J Adolesc Health (2008) 0.85
Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am J Hum Genet (2006) 0.85
Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. Br J Haematol (2011) 0.85
Optimum management of pediatric patients with fever and neutropenia. Indian J Pediatr (2004) 0.84
Central line-associated bloodstream infection in children: an update on treatment. Pediatr Infect Dis J (2013) 0.84
High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). Hum Vaccin Immunother (2013) 0.84